Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

Inhaled Carbon Monoxide at 200 ppm

Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.

OTHER

Inhaled Medical air

Inhaled Medical Air for up to 90 minutes daily for 3 days.

Trial Locations (7)

10065

Weill Cornell Medical College, New York

11215

New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn

27704

Duke Regional Hospital, Durham

27710

Duke University Hospital, Durham

63130

Washington University, St Louis

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Duke University

OTHER

collaborator

Durham VA Medical Center

FED

collaborator

New York Presbyterian Brooklyn Methodist Hospital

OTHER

collaborator

Duke Regional Hospital

OTHER

collaborator

U.S. Army Medical Research Acquisition Activity

FED

collaborator

Washington University School of Medicine

OTHER

lead

Brigham and Women's Hospital

OTHER